InstalabLoading...
InstalabLoading...
Pregnenolone sits at the top of a family tree. Your body makes it from cholesterol, and from there it branches out into cortisol, DHEA, testosterone, estrogen, and progesterone. Knowing your pregnenolone level gives you a look at the raw material your adrenal glands, gonads, and brain use to build every other steroid hormone you have.
This is an exploratory test, not a routine one. It is not part of any guideline-recommended screening panel, and published reference ranges vary across labs. What it can do is give someone curious about their hormone biology a baseline reading on a pathway that standard labs do not measure.
This test measures pregnenolone (the full name of the molecule is simply pregnenolone) in a blood sample, reported in picograms per milliliter or nanomoles per liter (both are very small concentration units). Modern labs use a specialized technique called LC-MS/MS (liquid chromatography with mass spectrometry), which separates and identifies hormones by their exact molecular weight. This method replaced older antibody-based tests because it is more specific.
The test captures unconjugated pregnenolone, which is the free form of the molecule. It does not measure pregnenolone sulfate, a chemically modified version that circulates at higher levels and responds differently to stress signals. If you want the sulfated form, that is a separate test.
Pregnenolone reflects how much raw material your body has available to build downstream hormones. It is the first step after cholesterol in the steroid pathway, and the enzyme that makes it (called CYP11A1 in the adrenal glands and gonads) is considered the rate-limiting gate for the whole system.
Beyond its role as a precursor, pregnenolone has direct activity of its own. Research has identified it as a modulator of brain receptors involved in mood and memory, and it appears to have anti-inflammatory effects through pathways in the immune system. That said, these mechanistic findings come largely from laboratory research, and the clinical meaning of a specific blood level in a healthy person is still being worked out.
The most established use for pregnenolone testing is evaluating a group of rare genetic conditions that disrupt steroid hormone production, grouped together as congenital adrenal hyperplasia. In one of these (called 3-beta-hydroxysteroid dehydrogenase deficiency), pregnenolone and a related molecule called 17-hydroxypregnenolone build up because the body cannot process them further. The 17-hydroxypregnenolone-to-cortisol ratio is the most reliable single number used to diagnose this form.
In another rare form called P450 oxidoreductase deficiency, pregnenolone, progesterone, and 17-hydroxypregnenolone are often elevated both at baseline and after a stimulation test. These are genetic conditions usually identified in childhood, not the kind of thing that typically surfaces in a healthy adult taking a curiosity test.
In a small study of people with adrenal tumors, 4 of 6 patients with adrenal carcinoma had elevated 17-hydroxypregnenolone, while people with other causes of cortisol excess (such as a pituitary tumor or an adrenal adenoma) had normal levels. A normal number does not rule out cancer, but an elevated 17-hydroxypregnenolone in that clinical context raises suspicion.
In premenopausal women with unexplained excess body hair growth (called idiopathic hirsutism), both pregnenolone and 17-hydroxypregnenolone tend to run high, which suggests altered steroid processing rather than a single enzyme defect.
A case-control study of 2,359 men and postmenopausal women in rural China found that people in the top quartile of pregnenolone had roughly one-fifth the odds of prediabetes (OR 0.23) and about half the odds of type 2 diabetes (OR 0.44) compared to those in the bottom quartile. The association held up after adjusting for standard risk factors. Because this was a snapshot in time rather than a long-term follow-up, the data cannot tell you whether low pregnenolone causes diabetes or whether something about diabetes lowers pregnenolone. Still, it is the clearest signal available that pregnenolone tracks with metabolic health in this population.
A 12-year follow-up of postmenopausal women (the B-FIT cohort) looked at whether pregnenolone predicted cancer. Pregnenolone itself showed no meaningful link to endometrial, ovarian, or colorectal cancer. The related molecule 17-hydroxypregnenolone did show connections in opposite directions: higher levels were linked to lower endometrial cancer risk but higher ovarian cancer risk. These findings are about 17-hydroxypregnenolone, not pregnenolone itself, and have not been replicated in larger studies.
An observational study of male shift workers found they had lower pregnenolone and testosterone compared to day workers. This suggests that chronic circadian rhythm disruption may dampen steroid production, though the finding comes from a single study and has not been tested with an intervention.
There are no consensus clinical cutpoints for pregnenolone. No professional society publishes risk tiers. The ranges below come from research-lab populations and should be treated as orientation, not verdicts. Age and sex matter more for this hormone than almost any other confounder, so use your own lab's age and sex-specific range if they provide one.
| Population | Research-Reported Range | What It Suggests |
|---|---|---|
| Premenopausal women | 31.2 to 135.2 pg/mL (98 to 426 pmol/L) | Typical range in reproductive-age women |
| Postmenopausal women | 16.2 to 68.0 pg/mL (51 to 214 pmol/L) | Lower baseline reflecting reduced ovarian steroid activity |
| Healthy adults (biphasic age curve) | Peak at ages 16 to 17, nadir at ages 37 to 38 | Levels naturally fall from late teens into late 30s, then partially rebound |
These ranges come from published research using LC-MS/MS measurement. Your lab may use a different assay with different cutpoints. Compare your result within the same lab over time for the most meaningful trend.
A single pregnenolone value is shakier ground than most blood tests. The within-person day-to-day variability has not been well characterized, but women in a single study spanned a fourfold range of healthy values (31.2 to 135.2 pg/mL), which is wide. Pregnenolone also follows a daily rhythm in the early part of the menstrual cycle, and it drops after meals. On top of biology, the sample itself is fragile: pregnenolone begins to degrade within an hour of the blood draw if the sample is not processed promptly.
This is why a trend matters more than any single number. A reasonable approach is to get a baseline draw, repeat it in 3 to 6 months under similar conditions (same lab, same time of day, same phase of menstrual cycle if applicable, same fasting status), and then track annually after that. If you are trying to change something about your hormones, a follow-up in 3 to 6 months gives you something to compare against.
Pregnenolone is one of the more fragile hormones to measure. Several factors can make a single reading unreliable.
If you are on any of these medications, the reading reflects the drug, not a natural baseline. Retest when off the interfering medication if possible, or interpret your number in that context.
Evidence-backed interventions that affect your Pregnenolone level
Pregnenolone is best interpreted alongside these tests.